Immunosuppressive Activity of Mycophenolate Mofetil

@article{Eugui1993ImmunosuppressiveAO,
  title={Immunosuppressive Activity of Mycophenolate Mofetil},
  author={E. Eugui and A. Allison},
  journal={Annals of the New York Academy of Sciences},
  year={1993},
  volume={685}
}
  • E. Eugui, A. Allison
  • Published 1993
  • Biology, Medicine
  • Annals of the New York Academy of Sciences

Topics from this paper

Identification of the Molecular Mechanisms underlying the Gastrointestinal Toxicity of the Immunosuppressants Mycophenolate Mofetil and Enteric-coated Mycophenolate Sodium using a Proteo-Metabolomic Approach
Mycophenolic acid (MPA) is the cornerstone of most immunosuppressive drug regimens after organ transplantation. However, gastrointestinal side effects diminish MPA's otherwise outstanding safety andExpand
Validation of the cell line LS180 as a model for study of the gastrointestinal toxicity of mycophenolic acid
TLDR
An in vitro model based on the human colon adenocarcinoma cell line LS180 was developed and it was concluded that LS180 cells are suitable to study the potential association between MPA metabolism and its negative effects on intestinal cells. Expand
Review of the immunosuppressant enteric-coated mycophenolate sodium
TLDR
EC-MPS presents physicians and patients with a valid alternative MPA therapy with a comparable efficacy and safety profile to MMF, and has demonstrated therapeutic equivalence toMMF 1000 mg b.i.d. in renal transplant patients. Expand
Therapeutic drug monitoring of immunosuppressants
TLDR
Recent advancements in the instrumentation and reagents designed for use with LC–MS detection systems are rapidly becoming an economically viable and practical approach for monitoring immunosuppressive drugs. Expand
Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion
TLDR
TDM of MMF has the potential to optimize therapy in pediatric transplantation as well as in nephrotic syndrome and future perspectives rather encompass approaches reflecting total immunosuppressive load than single drug TDM. Expand
Immunotherapies for thyroid eye disease.
  • G. Kahaly
  • Medicine
  • Current opinion in endocrinology, diabetes, and obesity
  • 2019
TLDR
Thyroid eye disease is a complex autoimmune disorder which causes substantial morbidity and quality of life, mental health, and socioeconomic status and targeted biologic therapies have shown promise, including teprotumumab (anti-IGFR) which appears to substantially reduce proptosis and rituximab ( anti-CD20) which reduces inflammation. Expand
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
TLDR
An up-to-date overview of the field is provided, the optimal management of Graves orbitopathy is outlined and the research developments in this area are summarized to highlight future research questions and direct future clinical trials. Expand
Systemic safety analysis of mycophenolate in Graves’ orbitopathy
TLDR
The risk–benefit ratio of low-dose mycophenolate treatment in active moderate-to-severe GO is highly favorable given its reassuring safety profile with low rate of mild- to-moderate SE and promising efficacy. Expand
Effect of Systematic Conversion to Generic Mycophenolate Mofetil (MMF) in Kidney Transplantation: A Single-Center Clinical Experience from Japan.
TLDR
Four cases could not maintain blood concentration of generic drugs of mycophenolate mofetil (MMF) and these cases discontinued to use the generic drugs thereafter due to unstable plasma concentration of MMF. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
The purine path to chemotherapy
  • G. Elion
  • Biology, Medicine
  • In Vitro Cellular & Developmental Biology
  • 2007
TLDR
Research on antimetabolites of nucleic acid purines led to drugs for the treatment of acute leukemia, gout and hyperuricemia, and herpesvirus infections, and for the prevention of organ transplant rejection. Expand
Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction.
TLDR
This review focuses on the phenotype, specificity, and function of the T cells mediating rejection responses against skin allografts, and on the immune mechanisms by which host T cells are either activated or rendered non-responsive by cellular populations within the graft. Expand
Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes.
  • S. Korsmeyer
  • Biology, Medicine
  • Annual review of immunology
  • 1992
TLDR
Molecular cloning of an aberrant Ig rearrangement in follicular lymphoma revealed Bcl-2, the first member of a new category of oncogenes: regulators of programmed cell death, which blocks apoptosis and maintains long-term immune responsiveness including B-cell memory. Expand
Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
TLDR
It is concluded that mizoribine selectively inhibits guanine ribonucleotide formation in purified T cells, whereas the effect of 6MP appears to be more dependent on adenine rib onucleotide depletion. Expand
Inhibition by mycophenolic acid of the transfer of mannose to lymphocytic cell membrane glycoproteins and cell adhesion
  • 1992
Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells.
TLDR
The low level of type II IMPDH mRNA in normal lymphocytes was up-regulated by phytohemagglutinin stimulation, and the type II mRNA expression in quiescent HL-60 cells was also elevated 2.8-fold by serum stimulation. Expand
RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1
TLDR
Preliminary evidence suggests that the drug prevents chronic rejection and was well tolerated in all dose groups, with only one adverse event possibly related to the drug (hemorrhagic gastritis). Expand
Carbohvdrate liaands for endothelial leukocyte adhe - 23 . 24 . 25 . 26 . 27 . 28 . 29 . 30 . sion molecule 1
  • Proc . Natl . Acad . Sci . USA
  • 1991
...
1
2
3
4
5
...